Kansas City, MONCT07209410Now EnrollingIRB Ready

Glaucoma Clinical Trial in Kansas City, MO

Access cutting-edge glaucoma treatment through this phase 4 clinical trial at a research site in Kansas City. Study-provided care at no cost to qualified participants.

Sponsored by Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,

Quick Self-Assessment

See if you qualify for this Kansas City location

Preparing your pre-screening questions…

Expert Care in Kansas City

Access glaucoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related glaucoma treatment provided free

Apply for This Kansas City Location

Check if you qualify for this glaucoma clinical trial in Kansas City, MO

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Kansas City

    Convenient for MO residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Kansas City site if eligible
  4. 4Begin participation

About This Glaucoma Study in Kansas City

To evaluate the effect of brimonidine tartrate 0.025% on conjunctival hyperemia in patients treated with netarsudil 0.02%/latanoprost 0.005% mono-therapy for intraocular pressure lowering.

Sponsor: Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,

Who Can Participate

Inclusion Criteria

1\. Adult patients 18-65 years old diagnosed with open-angle glaucoma or ocular hypertension. 2\. Currently on netarsudil 0.02%/latanoprost 0.005% monotherapy for a minimum of 2-6 weeks. 3\. Able to move from current topical glaucoma treatment to netarsudil 0.02%/latanoprost 0.005% for a minimum of 4 weeks or longer based on FDA recommended washout per drug classification prior to Visit 3. 4\. Experience conjunctival redness as graded on the Efron scale of at least grade 2 after minimum of 4 weeks on netarsudil 0.02%/latanoprost 0.005% mono-therapy or longer based on recommended washout per drug classification 4. Have a best corrected Visual Acuity by Snellen chart of 20/30 or better in study eye. 5\. Are willing and able to self-administer or have an able person available to assist with administration of study drug. Willing and able to comply with study procedures and attend follow-up visits.

Exclusion Criteria

Allergy or hypersensitivity to brimonidine or other components of brimonidine tartrate 0.025% or netarsudil 0.02%/latanoprost 0.005%.
Use of any other topical ocular medications.
Active ocular infection, inflammation unrelated to glaucoma therapy, uveitis, iritis or congenital aphakia.
Have pterygium/pinguecula, chemosis, episcleritis, scleritis (or any condition that may affect hyperemia grading) in the opinion of the investigator
Have moderate or severe dry eyes.
Pregnant, plan to become pregnant or breastfeeding.
Concurrent or past use in the last 90 days of vasoconstrictive ocular drops other than brimondine 0.025%
Have undergone previous incision IOP lowering surgeries.
Have undergone previous laser surgery for glaucoma (selective laser trabeculoplasty (SLT) or argon laser trabeculoplasty (ALT)), or microinvasive glaucoma surgery (MIGS) with 6 months of screening.
Have had intraocular or per-ocular surgery within the past 3 months.
Advanced glaucoma or c/d ratio greater than 0.8. Are non-responsive to topical treatment with netarsudil 0.02%/latanoprost 0.005%.
In the judgement of the investigator, have previous or currently active clinically significant systemic or ocular disease in either eye that could affect study outcomes.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Kansas City?

Yes, this clinical trial (NCT07209410) has an active research site in Kansas City, MO that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Glaucoma Treatment Options in Kansas City, MO

If you're searching for glaucoma treatment options in Kansas City, MO, this clinical trial (NCT07209410) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Kansas City research site is actively enrolling participants for this phase 4 clinical trial. You'll receive care from experienced glaucoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all glaucoma clinical trials near you to find additional studies recruiting in your area.

More Ulcerative Colitis Trials in Kansas City, MO

See all ulcerative colitis clinical trials recruiting in Kansas City — not just this study.

Browse Ulcerative Colitis Trials in Kansas City →

Browse More Trials by Condition

Ulcerative Colitis TrialsGlaucoma TrialsAll Conditions →

Ready to Join in Kansas City?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Kansas City, MO